Imrecoxib

395683-14-4

C21H23NO3S

10 mM in DMSO

Immunology/Inflammation

Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC₅₀ value of 18 nM, it also inhibits COX1- activity with an IC₅₀ value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect^[1]. In Vitro: Imrecoxib (BAP-909) (0.1-10 uM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells^[1]. In Vivo: Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours^[1].
Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis^[1].